Vasculogenic mimicry of acute leukemic bone marrow stromal cells

Leukemia

Volumn 23, Issue 6, 2009, Pages 1039-1048

  Mirshahi, P ^a,b   Rafii, A ^a   Vincent, L ^a,b   Berthaut, A ^a   Varin, R ^b   Kalantar, G ^a   Marzac, C ^a   Calandini, O A ^a   Marie, J P ^a   Soria, C ^b   Soria, J ^a   Mirshahi, M ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CD133 ANTIGEN; CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR; GUANOSINE TRIPHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN A; VASCULOTROPIN C;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADHERENT CELL; ARTICLE; BLOOD VESSEL PARAMETERS; BONE MARROW CELL; BONE MARROW CULTURE; CELL COUNT; CELL FUNCTION; CELL ISOLATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MICROVASCULAR DENSITY; MICROVASCULATURE; PRIORITY JOURNAL; STROMA CELL; SUPERNATANT; TUMOR VASCULARIZATION; VASCULOGENIC MIMICRY;

EID: 67349158886     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.10     Document Type: Article

References (37)

1. Folkman J. Tumor angiogenesis: A possible control point in tumor growth. Ann Intern Med 1975; 82: 96-100.
2. Moehler TM, Neben K, Ho AD, Goldschmidt H. Angiogenesis in hematologic malignancies. Ann Hematol 2001; 80: 695-705.
3. Mangi MH, Newland AC. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol 2000; 111: 43-51.
4. Matuszewski L, Persigehl T, Wall A, Meier N, Bieker R, Kooijman H et al. Assessment of bone marrow angiogenesis in patients with acute myeloid leukemia by using contrast-enhanced MR imaging with clinically approved iron oxides: Initial experience. Radiology 2007; 242 217-224.
5. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309.
6. Padró T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J et al Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-2644.
7. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815-821.
8. Dong X, Han ZC, Yang R. Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol 2007; 62: 105-118.
9. Yang R, Han ZC. Angiogenesis in hematologic malignancies and its clinical implications. Int J Hematol 2002; 75: 246-256.
10. De Bont ES, Rosati S, Jacobs S, Kamps WA, Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukemia: A possible role for vascular endothelial growth factor. Br J Haematol 2001; 113: 296-304.
11. Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002; 95: 1923-1930.
12. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-521.
13. Padró T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H et al Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002; 16: 1302-1310.
14. Fiedler W, Graeven U, Ergün S, Verago S, Kilic N, Stockschläder M et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89 1870-1875.
15. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
16. Schneider P, Vasse M, Sbaa-Ketata E, Lenormand B, Hong L, Soria C et al. The growth of highly proliferative acute lymphoblastic leukemia may be independent of stroma and/or angiogenesis. Leukemia 2001; 15: 1143-1145.
17. Faderl S, Do KA, Johnson MM, Keating M, O'brien S, Jilani I et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 2005; 106: 4303-4307.
18. Duhrsen U, Knieling G, Beecken W, Neumann S, Hossfeld DK. Chimaeric cultures of human marrow stroma and murine leukemia cells: Evidence for abnormalities in the haemopoietic microenvironment in myeloid malignancies and other infiltrating marrow disorders. Br J Haematol 1995; 90: 502-511.
19. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001; 29: 448-457.
20. Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992; 79: 2370-2377.
21. Gilmore MJ, Prentice HG, Blacklock HA, Janossy G, Hoffbrand AV. A technique for rapid isolation of bone marrow mononuclear cells using Ficoll-Metrizoate and the IBM 2991 blood cell processor. Br J Haematol 1982; 50: 619-626.
22. Mirshahi P, Toprak SK, Faussat AM, Dubrulle S, Marie JP, Soria C et al. Malignant hematopoietic cells induce an increased expression of VEGFR-1 and VEGFR-3 on bone marrow endothelial cells via AKT and mTOR signalling pathways. Biochem Biophys Res Commun 2006; 349: 1003-1010.
23. Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 2007; 21: 1921-1930.
24. Mirshahi F, Pourtau J, Li H, Muraine M, Trochon V, Legrand E et al SDF-1 activity on microvascular endothelial cells: Consequences on angiogenesis in in vitro and in vivo models. Thromb Res 2000; 99: 587-594.
25. Chen T, Bai H, Shao Y, Arzigian M, Janzen V, Attar E et al. Stromal cell-derived factor-1/CXCR4 signaling modifies the capillary-like organization of human embryonic stem cell-derived endothelium in vitro. Stem Cells 2007; 25: 392-401.
26. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 2006; 66: 9054-9064.
27. Hermann C, Assmus B, Urbich C, Zeiher AM, Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20 402-409.
28. Riccioni R, Diverio D, Mariani G, Buffolino S, Riti V, Saulle E et al Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts. Stem Cells 2007; 25: 1862-1871.
29. Cheng HL, Steinway ML, Russell JW, Feldman EL. GTPases and phosphatidylinositol 3-kinase are critical for insulin-like growth factor-I-mediated Schwann cell motility. J Biol Chem 2000; 275 27197-27204.
30. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J et al Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol 1999; 155: 739-752.
31. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat Rev Cancer 2003; 3: 411-421.
32. Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 2006; 16: 693-698.
33. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000; 156: 361-381.
34. Scavelli C, Nico B, Cirulli T, Ria R, Di Pietro G, Mangieri D et al Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 2008; 27: 663-674.
35. Zahiragic L, Schliemann C, Bieker R, Thoennissen NH, Burow K, Kramer C et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007; 21: 1310-1312.
36. Vincent L, Albanese P, Bompais H, Uzan G, Vannier JP, Steg PG et al Insights in the molecular mechanisms of the anti-angiogenic effect of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Thromb Haemost 2003; 89: 530-537.
37. Pille JY, Li H, Blot E, Bertrand JR, Pritchard LL, Opolon P et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: Safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther 2006; 17: 1019-1026.